Dr. Cindy Leissinger
MD
Biography
Dr. Cindy Leissinger is currently Professor of Medicine, and Clinical Professor of Pediatrics and Pathology at Tulane University and is the Director Emeritus of the Louisiana Center for Bleeding and Clotting Disorders. She is a fellow of the American College of Physicians and a member of the American Society of Hematology. Dr. Leissinger has been a member of the Hemostasis and Thrombosis Research Society since its inception and has served the society in numerous leadership positions, recently concluding a term as the society’s president.
Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.
In addition to caring for patients with coagulation disorders, Dr. Leissinger oversees an active research program that receives funding from the National Institutes of Health as well as numerous other federal and industry sources. She participates in several clinical research groups and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.
Key Publications
-
Leissinger C, Josephson C, Granger S, Konkle B, Kruse-Jarres R, Ragni M, Journeycake J, Neufeld E, Marder V, Assmann S, for the RICH Study Investigators. Rituximab for the treatment of inhibitors in hemophilia A: A phase II study. Thromb Haemost. 2014 Jun; 12;112(3).
-
Leissinger C, Carcao M, Gill J, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with bleeding disorders. Haemophilia. 2014 Mar;20(2):158-67.
-
Gringeri A, Leissinger C, Cortesi P, Jo H, Fusco F, Riva S, Mantovani L, and the ProFEIBA Study Group. Health related quality of life in patients with haemophilia and inhibitors on prophylaxis with an anti-inhibitor complex concentrate (AICC): Results from the ProFEIBA Study. Haemophilia. 2013 Sep;19(5):736-43.
-
Leissinger C, Gringeri A, Antmen B, Berntorp B, Biasoli B, Carpenter C, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu M, Windyga J, Zülfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011 Nov;365:1684-92.
-
Leissinger C, Cooper D and Wilke C. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe hemophilia A. Haemophilia. 2011 Nov; 17(6):884-889.
Key Institutions
-
Tulane University School of Medicine
Hematology/Oncology
New Orleans, USA
Current Positions/Chairs
-
Professor of Medicine
Clinical Professor of Pediatrics and Pathology, Tulane University -
Director Emeritus
Louisiana Center for Bleeding and Clotting Disorders -
Chief
Section of Hematology/Oncology, Tulane University
Research Interests
-
Factor VIII inhibitors
-
Treatment of patients with inhibitors
-
Thromboelastography in patients with thrombophilic states
Research Activities
-
Dr. Leissinger participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.
Publications
Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis
Authors
Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).
Citation
Haemophilia. E-Pub July 10, 2018
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia
Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia
Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5):e447 - e450
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators
Citation
57th American Society of Hematology Meeting 2015.
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
Prophylaxis practices in children and adults with inhibitors.
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation
Journal of Thrombosis and Haemostasis 2015, 13 (S2), # PO270-MON, 360.